Traditional medicine Taeeumjowitangkagambang exerts antiobesity and hypolipidemic effects via antioxidant enzyme enhancement

Phytotherapy Research

Volumn 24, Issue 11, 2010, Pages 1700-1709

  Park, Cheol Hwan ^a   Jeong, Soo Jin ^a   Lee, Hyo Jeong ^a   Lee, Eun Ok ^a   Bae, Hyunsu ^a   Lee, Min Ho ^a   Kim, Sun Hyung ^a   Jung, Hee Jae ^a   Ahn, Kyoo Seok ^a   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Antioxidant enzymes; Hyperlipidemia; Obesity; Taeeumjowitangkagambang

Indexed keywords

ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CATALASE; GLUTATHIONE PEROXIDASE; HERBACEOUS AGENT; LEPTIN; LOW DENSITY LIPOPROTEIN; SUPEROXIDE DISMUTASE; TAEEUMJOWITANGKAGAMBANG; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; EPIDIDYMIS FAT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERLIPIDEMIA; KOREAN MEDICINE; LIPID BLOOD LEVEL; LIPID DIET; LIPID STORAGE; MALE; NONHUMAN; OBESITY; RAT; WEIGHT GAIN;

3T3-L1 CELLS; ANIMALS; ANTI-OBESITY AGENTS; ANTIOXIDANTS; BODY WEIGHT; CATALASE; CHOLESTEROL; GLUTATHIONE PEROXIDASE; HYPOLIPIDEMIC AGENTS; LEPTIN; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LIVER; MALE; MEDICINE, KOREAN TRADITIONAL; MICE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRIGLYCERIDES;

RATTUS;

EID: 78049415813     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3179     Document Type: Article

References (39)

1. Abenhaim L, Moride Y, Brenot F et al. 1996. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335: 609-616.
2. Aebi H, Suter H. 1971. Acatalasemia. Adv Hum Genet 2: 143-199.
3. Akbas F, Gasteyger C, Sjodin A, Astrup A, Larsen TM. 2009. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 10: 58-67.
4. Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
5. Bray GA, Greenway FL. 1999. Current and potential drugs for treatment of obesity. Endocr Rev 20: 805-875.
6. Brennan AM, Mantzoros CS. 2006. Drug insight: the role of leptin in human physiology and pathophysiology - emerging clinical applications. Nat Clin Pract Endocrinol Metab 2: 318-327.
7. Brown WV, Fujioka K, Wilson PW, Woodworth KA. 2009. Obesity: why be concerned? Am J Med 122: S4-S11.
8. Capel ID, Dorrell HM. 1984. Abnormal antioxidant defence in some tissues of congenitally obese mice. Biochem J 219: 41-49.
9. Cooke D, Bloom S. 2006. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 5: 919-931.
10. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O. 2007. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Ann Nutr Metab 51: 134-138.
11. Do EU, Piao LZ, Choi G et al. 2006. The high throughput screening of neuropeptide FF2 receptor ligands from Korean herbal plant extracts. Peptides 27: 997-1004.
12. Fernandez-Robredo P, Moya D, Rodriguez JA, Garcia-Layana A. 2005. Vitamins C and E reduce retinal oxidative stress and nitric oxide metabolites and prevent ultrastructural alterations in porcine hypercholesterolemia. Invest Ophthalmol Vis Sci 46: 1140-1146.
13. Fishman AP. 1999. Aminorex to fen/phen: an epidemic foretold. Circulation 99: 156-161.
14. Friedman JM, Halaas JL. 1998. Leptin and the regulation of body weight in mammals. Nature 395: 763-770.
15. Furukawa S, Fujita T, Shimabukuro M et al. 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761.
16. Greenway FL, Bray GA. 2008. Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr Pract 14: 697-703.
17. Guo AJ, Choi RC, Cheung AW et al. 2009. Stimulation of apolipoprotein A-IV expression in Caco-2/TC7 enterocytes and reduction of triglyceride formation in 3T3-L1 adipocytes by potential anti-obesity Chinese herbal medicines. Chin Med 4: 5.
18. Haslam DW, James WP. 2005. Obesity. Lancet 366: 1197-1209.
19. Jeong S, Chae K, Jung YS et al. 2008. The Korean traditional medicine Gyeongshingangjeehwan inhibits obesity through the regulation of leptin and PPARalpha action in OLETF rats. J Ethnopharmacol 119: 245-251.
20. Kim SO, Yun SJ, Jung B et al. 2004. Hypolipidemic effects of crude extract of adlay seed (Coix lachrymajobi var. mayuen) in obesity rat fed high fat diet: relations of TNF-alpha and leptin mRNA expressions and serum lipid levels. Life Sci 75: 1391-1404.
21. Kim SO, Yun SJ, Lee EH. 2007. The water extract of adlay seed (Coix lachrymajobi var. mayuen) exhibits anti-obesity effects through neuroendocrine modulation. Am J Chin Med 35: 297-308.
22. Kobatake Y, Saito M, Kuroda K, Kobayashi S, Innami S. 1987. Influence of fish consumption on serum lipid and lipid peroxide concentrations in middle aged subjects. J Jpn Soc Nutr Food Sci 40: 103-107.
23. Levine RL, Garland D, Oliver CN et al. 1990. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186: 464-478.
24. Mates JM, Perez-Gomez C, Nunez de Castro I. 1999. Antioxidant enzymes and human diseases. Clin Biochem 32: 595-603.
25. McGowan MW, Artiss JD, Strandbergh DR, Zak B. 1983. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 29: 538-542.
26. Misra HP, Fridovich I. 1972. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247: 3170-3175.
27. 2+, and an anion-exchange resin. Clin Chem 24: 1504-1508.
28. Ohkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358.
29. Oliver CN, Ahn BW, Moerman EJ, Goldstein S, Stadtman ER. 1987. Age-related changes in oxidized proteins. J Biol Chem 262: 5488-5491.
30. Oyanagui Y. 1984. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 142: 290-296.
31. Ozata M, Mergen M, Oktenli C et al. 2002. Increased oxidative stress and hypozincemia in male obesity. Clin Biochem 35: 627-631.
32. Paglia DE, Valentine WN. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169.
33. Rasouli N, Molavi B, Elbein SC, Kern PA. 2007. Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab 9: 1-10.
34. Reaven GM. 1988. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
35. Richmond W. 1976. Use of cholesterol oxidase for assay of total and free cholesterol in serum by continuous-flow analysis. Clin Chem 22: 1579-1588.
36. Rogers QR, Harper AE. 1965. Amino acid diets and maximal growth in the rat. J Nutr 87: 267-273.
37. Sharma AM, Kushner RF. 2009. A proposed clinical staging system for obesity. Int J Obes (Lond) 33: 289-295.
38. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. 2005. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 142: 525-531.
39. Wang Y, Deng M, Zhang SY, Zhou ZK, Tian WX. 2008. Parasitic loranthus from Loranthaceae rather than Viscaceae potently inhibits fatty acid synthase and reduces body weight in mice. J Ethnopharmacol 118: 473-478.